It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diagnosis of myelodysplastic syndrome (MDS) mainly relies on a manual assessment of the peripheral blood and bone marrow cell morphology. The WHO guidelines suggest a visual screening of 200 to 500 cells which inevitably turns the assessor blind to rare cell populations and leads to low reproducibility. Moreover, the human eye is not suited to detect shifts of cellular properties of entire populations. Hence, quantitative image analysis could improve the accuracy and reproducibility of MDS diagnosis. We used real-time deformability cytometry (RT-DC) to measure bone marrow biopsy samples of MDS patients and age-matched healthy individuals. RT-DC is a high-throughput (1000 cells/s) imaging flow cytometer capable of recording morphological and mechanical properties of single cells. Properties of single cells were quantified using automated image analysis, and machine learning was employed to discover morpho-mechanical patterns in thousands of individual cells that allow to distinguish healthy vs. MDS samples. We found that distribution properties of cell sizes differ between healthy and MDS, with MDS showing a narrower distribution of cell sizes. Furthermore, we found a strong correlation between the mechanical properties of cells and the number of disease-determining mutations, inaccessible with current diagnostic approaches. Hence, machine-learning assisted RT-DC could be a promising tool to automate sample analysis to assist experts during diagnosis or provide a scalable solution for MDS diagnosis to regions lacking sufficient medical experts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Technische Universität Dresden, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Technische Universität Dresden, Center for Regenerative Therapies Dresden (CRTD), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
2 Technische Universität Dresden, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Max Planck Institute for the Science of Light & Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany (GRID:grid.419562.d) (ISNI:0000 0004 0374 4283); University Hospital Carl Gustav Carus Dresden, Medical Department I, Dresden, Germany (GRID:grid.412282.f) (ISNI:0000 0001 1091 2917)
3 University Hospital Carl Gustav Carus Dresden, Medical Department I, Dresden, Germany (GRID:grid.412282.f) (ISNI:0000 0001 1091 2917)
4 University Hospital Carl Gustav Carus Dresden, Medical Department III, Dresden, Germany (GRID:grid.412282.f) (ISNI:0000 0001 1091 2917); Center for Healthy Aging, Dresden, Germany (GRID:grid.412282.f)
5 Max Planck Institute for the Science of Light & Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany (GRID:grid.419562.d) (ISNI:0000 0004 0374 4283)
6 Universität Greifswald, Zentrum für Innovationskompetenz: Humorale Immunreaktionen in Kardiovaskulären Erkrankungen, Greifswald, Germany (GRID:grid.5603.0)
7 Technical University of Munich, Department of Medicine III: Hematology and Oncology, School of Medicine, Klinikum Rechts Der Isar, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
8 University Hospital Carl Gustav Carus Dresden, Medical Department III, Dresden, Germany (GRID:grid.412282.f) (ISNI:0000 0001 1091 2917); German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Center for Healthy Aging, Dresden, Germany (GRID:grid.7497.d)
9 University Hospital Carl Gustav Carus Dresden, Medical Department I, Dresden, Germany (GRID:grid.412282.f) (ISNI:0000 0001 1091 2917); German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
10 Technische Universität Dresden, Center for Regenerative Therapies Dresden (CRTD), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
11 German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Leipzig University Hospital, Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig, Germany (GRID:grid.411339.d) (ISNI:0000 0000 8517 9062)